SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 20, 2004
Savient Pharmaceuticals, Inc.
(Exact name of issuer as specified in its charter)
Delaware | | 0-15313 | | 13-3033811 |
(State or Other Jurisdiction
of Incorporation) | | (Commission File Number) | | (IRS Employer
Identification No.) |
| | | | |
One Tower Center, 14th Floor
East Brunswick, New Jersey | | 08816 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (732) 418-9300
None.
(Former Name or Former Address, if Changed Since Last Report.)
ITEM 7. | FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. |
| |
| (c) | Exhibits. |
| | | |
| | | 99.1 | Press release issued by Savient Pharmaceuticals, Inc. (the “Company”) on February 20, 2004. |
| | | | |
ITEM 12. | RESULTS OF OPERATIONS AND FINANCIAL CONDITION. |
| | | | |
On February 20, 2004, the Company announced its financial results for the three months and year ended December 31, 2003. A copy of the Company’s press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | SAVIENT PHARMACEUTICALS, INC. |
| | | | | (Registrant) |
| | | | | |
| | | | | |
| | | | | By: | /s/ Sim Fass | |
| | | | | | Sim Fass |
| | | | | | Chief Executive Officer |
| | | | | | |
Dated: February 20, 2004 | | | | | | |
3
